Pfizer's submission of the latest stability data for the new crown vaccine is expected to increase storage/shipping flexibility

The new mRNA crown vaccine, developed jointly by Pfizer and BioNTech, has been approved for use in many countries and regions.
in Phase 3 clinical trials, COVID-19, which prevents symptoms, is more than 90% protective.
, however, the mRNA vaccine is labeled EUA and must be stored in ultra-low temperature refrigerators from -80oC to -60oC.
can be kept at this temperature for up to six months.
this strict requirement for temperature preservation is inconvenient for the transport and storage of vaccines.
to the FDA includes stability data for different batches produced during the development of the new crown vaccine over the past nine months.
include batches used in the earliest clinical trials, as well as batches currently in commercial production.
data will also be submitted to global regulators in the coming weeks.
"We have been conducting ongoing stability studies to support commercial-scale vaccine production, with the goal of making vaccines as accessed as possible to medical personnel and people around the world."
," said Albert Bourla, Pfizer's chairman and chief executive.
if approved, this new storage option will provide pharmacies and vaccination centres with greater flexibility in how they manage their vaccine supplies.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
: s1. PFIZER AND BIONTECH SUBMIT COVID-19 VACCINE STABILITY AT STANDARD FREEZER TO TO U.S. FDA. Retrieved February 19, 2021, from